NEC Group's blood testing service 'FonesVisuas' adopted by Royal Healthcare, a medical institution for high-net-worth individuals in Singapore
NQ Score
56/100
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What is the FonesVisuas Test and what does it do?
- A: The FonesVisuas Test is a blood testing service developed by NEC Group that analyzes proteins from a small blood sample to visualize the body's current state and predict the risk of developing certain diseases.
- Q: Which medical institution in Singapore has adopted NEC's FonesVisuas Test?
- A: Royal Healthcare, a medical institution for high-net-worth individuals and a subsidiary of Sojitz Corporation, has adopted NEC's FonesVisuas Test.
- Q: What types of diseases can the FonesVisuas Test predict the risk for?
- A: The FonesVisuas Test can predict the risk of developing diseases such as dementia, myocardial infarction, stroke, lung cancer, chronic kidney failure, and prostate cancer within the next few years.
- Q: What is the primary goal of Royal Healthcare in offering the FonesVisuas Test?
- A: Royal Healthcare aims to improve people's quality of life by guiding individuals in a 'pre-symptomatic' state to adopt healthier lifestyle habits and prevent future diseases.
- Q: What is NEC's future plan for the FonesVisuas service?
- A: NEC intends to expand the sales of FonesVisuas overseas, with a particular focus on the APAC region, to contribute to the global improvement of healthcare quality.